Pharmacological Secondary Prevention of Ischemic Stroke.
- Author:
Han Jin CHO
1
;
Tae Ho KANG
Author Information
- Publication Type:Review
- Keywords: antiplatelet agent; anticoagulant; secondary prevention; ischemic stroke
- MeSH: Anticoagulants; Arteries; Atherosclerosis; Blood Platelets; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Secondary Prevention*; Stroke*
- From:Brain & Neurorehabilitation 2014;7(2):76-85
- CountryRepublic of Korea
- Language:English
- Abstract: The causes of ischemic stroke are widely diverse, ranging from large artery atherosclerosis to cardioembolism, and it is important to use preventive therapy toward the goal reducing the future risk of recurrent ischemic stroke, myocardial infarction, and vascular death. Antithrombotic therapy is one of the fundamental medical approaches for secondary prevention of ischemic stroke, which is broadly divided into two general categories, those that exert their effect via platelet inhibition (antiplatelet agents), and those that influence various factors in the clotting cascade (anticoagulants). In general, the clinical guidelines recommend antiplatelet agents for patients with non-cardioembolic stroke, while anticoagulants is indicated for patients with presumed or proven cardioembolic stroke. Many clinical trials have attempted to test the efficacy and safety of antithrombotics in ischemic stroke. This review will discuss on currently available antithrombotic agents that have demonstrated efficacy for secondary prevention of ischemic stroke.
